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Background
The M184V mutation confers resistance to lamivudine
and emtricitabine and falls within a HLA-A2 restricted
CTL epitope, RT181-189, suggesting that it could be pos-
sible to vaccinate against drug resistance. In ART naïve
patients, CTL directed against this epitope recognize both
the wild-type 184M peptide, and the 3TC-resistant 184V
peptide, while in patients with 3TC-resistant virus it is
possible to detect CTL against the 184V peptide that do
not cross-react with the 184M peptide. To determine
whether the 184V or the 184M peptide would be the best
candidate for therapeutic vaccination, we studied the spe-
cificity and functional avidity of clones and cell lines spe-
cific for the RT181-189 epitope.
Methods
CTL lines and clones were obtained from PBMC of one
ART naïve HLA-A2+ patient and two HLA-A2+ patients
with lamivudine-resistant virus. Functional responses to a
panel of variant peptides were studied using IFN-gamma
ELISPOT.
Results
One 184M/184V cross-reactive clone and two CTL lines
specific for 184V were obtained. The cross-reactive clone
showed high functional avidity (EC50 100 pM) for both
184M and 184V peptides, and also recognized 184I,
184A, 184G, 184F and 184D mutant peptides. Both cell
lines from patients with 3TC-resistant virus showed selec-
tivity for 184V. Although the functional avidities of the
two cell lines were lower (EC50 1 nM and 1 μM) than that
found in the cross-reactive clone, they fell within the
range of values observed in PBMC from HLA-A2+ ART-
naïve patients showing a cross-reactive ELISPOT response
to the 184M and 184V peptides.
Conclusion
The CTL response directed specifically against the 184V
peptide is characterized by high selectivity, and its func-
tional avidity is similar to that of the cross-reactive
response generated against the 184M peptide.
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